Recursion Pharmaceuticals (NASDAQ: RXRX) stock dropped over 17% this week. An analyst cut the price target, and executives sold large amounts of stock. Morgan Stanley’s Sean Laaman lowered the fair value assessment to $4.80 per share. CEO Christopher Gibson and CRO Najit Khan sold shares to meet tax obligations. Biotech stocks are volatile, so these developments can impact company performance.

Investors should not base their decisions solely on these events. The Motley Fool’s Stock Advisor team did not select Recursion Pharmaceuticals as one of the top 10 stocks to buy now. Stock Advisor’s total average return is 1,045%, outperforming the S&P 500. Join Stock Advisor for access to the latest top 10 list.

Stock Advisor returns as of August 18, 2025. Eric Volkman and The Motley Fool have no positions in the mentioned stocks. “Why Recursion Pharmaceuticals Stock Caught a Cold This Week” was originally published by The Motley Fool.

Read more at Yahoo Finance: Why Recursion Pharmaceuticals Stock Caught a Cold This Week